MAPT and Cognitive impairment: In terms of biomarkers-the median pTau217 level was 0.65 for CN-1.34 for EMCI-and 2.19 for LMCI (p = 0.017)-suggesting an increase in tau pathology as the cognitive impairment worsened (Table 1).